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Abstract
Introduction—The prediction of late effects after radiotherapy in organs outside a treatment
field requires accurate estimations of out-of-field dose. However, out-of-field dose is not
calculated accurately by commercial treatment planning systems (TPSs). The purpose of this study
was to develop and test an analytical model for out-of-field dose during craniospinal irradiation
(CSI) from photon beams produced by a linear accelerator.
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Materials & Methods—In two separate evaluations of the model, we measured absorbed dose
for a 6-MV CSI using thermoluminescent dosimeters placed throughout an anthropomorphic
phantom and fit the measured data to an analytical model of absorbed dose versus distance outside
of the composite field edge. These measurements were performed in two separate clinics—The
University of Texas MD Anderson Cancer Center (MD Anderson) and the American University of
Beirut Medical Center (AUBMC)—using the same phantom but different linear accelerators and
TPSs commissioned for patient treatments. The measurement at AUBMC also included in-field
locations. Measured dose values were compared to those predicted by TPSs and parameters were
fit to the model in each setting.
Results—In each clinic, 95% of the measured data were contained within a factor of 0.2 and one
root mean square deviation of the model-based values. The root mean square deviations of the

*

Corresponding author: Phillip J. Taddei, Ph.D., Department of Radiation Physics, The University of Texas MD Anderson Cancer
Center, 1515 Holcombe Blvd., Unit 1202, Houston, TX 77030 USA. Tel.: +1-713-563-3771; Fax: +1-713-563-6949;
pt06@aub.edu.lb.
Each author does not have a conflict of interest.

Taddei et al.

Page 2

Author Manuscript

mathematical model were 0.91 cGy/Gy and 1.67 cGy/Gy in the MD Anderson and AUBMC
clinics, respectively. The TPS predictions agreed poorly with measurements in regions of sharp
dose gradient, e.g., near the field edge. At distances greater than 1 cm from the field edge, the TPS
underestimated the dose by an average of 14% ± 24% and 44% ± 19% in the MD Anderson and
AUBMC clinics, respectively. The in-field measured dose values of the measurement at AUBMC
matched the dose values calculated by the TPS to within 2%.
Conclusions—Dose algorithms in TPSs systematically underestimated the actual out-of-field
dose. Therefore, it is important to use an improved model based on measurements when
estimating out-of-field dose. The model proposed in this study performed well for this purpose in
two clinics and may be applicable in other clinics with similar treatment field configurations.
Keywords
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craniospinal irradiation; out-of-field dose; anthropomorphic phantom; thermoluminescent
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1. Introduction
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Modern radiotherapy techniques seek to cure or control local disease while minimizing
acute and late-occurring side effects from radiation. These radiogenic side effects most
frequently occur in or near the treatment site but may occur throughout the body because of
both in-field and out-of-field radiation exposures (Diallo et al 2009, Armstrong et al 2010).
Radiation that contributes to out-of-field, or stray, dose originates in the treatment unit (i.e.,
leakage radiation and scatter radiation emanating from the treatment head) and in the patient
(i.e., patient scatter radiation). Although the amount of stray radiation is small compared to
therapeutic doses, they are unavoidable and, in some cases, non-negligible. Exposure to
stray radiation increases the risk of biologic detriment, that is, the risk of stochastic effects,
including radiogenic cancer, and the severity of deterministic effects, including
cataractogenesis. Therefore, it is important to have models that can predict the out-of-field
dose from radiation therapy in order to minimize the out-of-field dose to normal tissues
while still achieving the desired dose to targeted tissues.
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Treatment planning systems (TPSs) are used to model treatment fields that deliver absorbed
dose to a clinical target volume while minimizing the dose in normal tissues, ensuring dose
is below population-based tolerance levels and avoiding non-target critical structures
(Bentzen et al 2010). A great deal of attention has been paid in the literature to the
development of a variety of algorithmic models to accurately predict the in-field dose
(Mackie et al 1985, Mohan et al 1986, Ahnesjo 1989, Papanikolaou et al 1993,
Papanikolaou et al 2004, Sievinen et al 2005, Vassiliev et al 2010, Han et al 2011).
However, despite the many decades of research on TPS dose modeling, the accuracy of
some commercial TPSs beyond a few centimeters outside the treatment field is poor (Taylor
and Kron 2011). For example, a recent study by Howell et al (2010) reported that a widelyused commercial TPS systematically underestimated the out-of-field dose by an average of
40% for a mantle-field irradiation. Huang et al (2013) found a similar result using a different
commercial TPS to calculate dose for three modern radiotherapy treatments.
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Compared to in-field dose, relatively less attention has been paid to algorithms to model outof-field doses. Through water-phantom measurements, Stovall et al (1995) showed that a
key parameter for modeling out of field dose is the distance from the field edge. In addition,
it may be necessary to take into account dependencies on the treatment apparatus (e.g.,
radiotherapy equipment and its shielding) and the treatment technique (e.g., energy, field
size, source-to-skin distance, and treatment site) (Taylor and Kron 2011). A number of other
out-of-field dose studies involving measurements of photons produced from electron linear
accelerators have been performed (Kase et al 1983, Stovall et al 1995, Howell et al 2006,
Kry et al 2007, Wang and Xu 2008, Fontenot et al 2009, Georgiev 2009, Scarboro et al
2010, Ruben et al 2011, Kaderka et al 2012), as have Monte Carlo simulations (Kry et al
2006, Bednarz and Xu 2008, 2009, Athar et al 2010, Kry et al 2010). Most out-of-field dose
modeling studies have applied simple empirical analytical methods or Monte Carlo
techniques. The empirical models neglect most dependencies and are simple and
computationally fast while Monte Carlo simulations typically model more dependencies and
result in a high level of accuracy but are consequently more complex geometrically and
slower computationally.
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Modeling out-of-field dose is particularly important for risk estimation, especially for the
treatment of children (Stovall et al 2006, Newhauser and Durante 2011). One of the most
common radiotherapies for children with cancer is craniospinal irradiation (CSI). Several
dosimetric studies on patients receiving CSI neglected out-of-field doses (St Clair et al
2004, Mu et al 2005, Cochran et al 2008, Merchant et al 2008, South et al 2008, Fogliata et
al 2011, Yoon et al 2011, Howell et al 2012). Recently, studies on CSI with proton beams
have included stray dose modeling using Monte Carlo methods (Newhauser et al 2009,
Taddei et al 2009a, Taddei et al 2009b, Athar et al 2010, Taddei et al 2010a, Taddei et al
2010b, Athar and Paganetti 2011, Perez-Andujar et al 2013, Zhang et al in review). Also
recently, analytical models for modeling out-of-field dose from proton therapy have been
developed (Zheng et al 2007a, Zheng et al 2007b, Zhang et al 2010); similar analytical
models for photon CSI are lacking despite the globally broader use compared to proton CSI.
A few very recent studies have estimated out-of-field dose photon CSI (Athar et al 2010,
Perez-Andujar et al 2013). However, none of these studies has proposed or tested an
analytical model to predict out-of-field dose from photon CSI.
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The objective of this study was to develop an analytical model that estimates out-of-field
dose from photon CSI. To accomplish this objective, we measured the out-of-field dose by
delivering CSI to an anthropomorphic phantom loaded with thermoluminescent dosimeters
(TLDs) and developed an analytical model using the measured data. To test whether the
model described the system accurately, the model was applied in two independent clinics
employing different electron linear accelerators. The resulting, tested model estimates outof-field dose as a function of distance from the field edge (i.e., from the 50% isodose
surface).
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2. Methods and Materials
2.1. Treatment apparatus in each clinic
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Measurements of absorbed dose for CSI were made in two independent clinics: The
University of Texas MD Anderson Cancer Center (MD Anderson) and the American
University of Beirut Medical Center (AUBMC). At MD Anderson, the photon CSI was
delivered with a clinical linear accelerator (Varian Clinac 2100, Varian Medical Systems,
Inc., Palo Alto, California), equipped with a multileaf collimator (Millennium MLC 120Leaf, Varian Medical Systems, Inc., Palo Alto, California). At AUBMC, the photon CSI was
delivered with a different clinical linear accelerator (Artiste, Siemens Medical Solutions
USA, Inc., Malvern, Pennsylvania) (Tacke et al 2008, Kluter et al 2011) in clinical
operation at the American University of Beirut Medical Center (AUBMC), which is
equipped with a multileaf collimator (160 MLC, Siemens Healthcare, Erlangen, Germany).
The multileaf collimator was the only accessory used to shape the beam. We attempted to
control for confounding factors that might influence comparisons of the results between the
two settings by using consistent methods in both clinics. For example, the same phantom
and the same type of TLDs were used in each measurement, and the same data analysis
methods were applied in each case. However, to ensure clinical realism, slightly different
field setups were designed according to the standards of care for photon CSI in the
respective clinics, as described in the next section. In each clinic, the TPS, CT scanner, and
linear accelerator were commissioned previously for clinical use following widely-accepted
procedures (Mutic et al 2003, Das et al 2008, Klein et al 2009).
2.2. Treatment planning, phantom, and imaging
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Treatment plans were created following the clinical standards of care for CSI of the central
nervous system at each institution. In both settings, the field orientations included lateral
opposed cranial fields (right and left) and two posterior-anterior spinal fields (upper and
lower). At MD Anderson, the clinical standard of care for photon CSI was followed to
design a treatment plan using 6-MV photon fields delivered with the field-in-field technique,
with an additional lower-spine field. At AUBMC, the clinical standard of care for photon
CSI was followed to design a treatment plan using 6-MV photon fields delivered with threedimensional conformal radiotherapy. For the purposes of this study, which investigated outof-field dose, the small difference in the irradiation techniques (i.e., additional fields) had
little impact on the results of this study because the contribution to out-of-field dose from
leakage radiation for each field was proportional to the monitor units of the field, and the
additional lower spine field for the field-in-field technique amounted to less than 2.5% of the
monitor units for the CSI treatment. Therefore, for the purpose of developing and testing a
model for estimating out-of-field dose in CSI, the two CSI techniques were very similar.
Because this study was concerned with out-of-field dose and the dose was delivered in a
single fraction, the junctions of the fields were not feathered.
In each clinic, an anthropomorphic phantom (ATOM® Adult Male 701, Computerized
Imaging Reference Systems, Inc., Norfolk, Virginia) was imaged, and treatment plans were
created as if it were a patient diagnosed with medulloblastoma. The phantom was
constructed to represent a reference man 173 cm tall and weighing 73 kg. The phantom was
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sectioned transaxially into 2.5-cm-thick slices, and the slices used in this study extended
from the head to the pelvis, yielding 40 slices in total. Each slice contained a matrix of 0.5cm-diameter detector plugs with grid spacing of 1.5 cm × 1.5 cm. Additional detector plugs
were placed in locations for optimization of organ doses. Materials in the phantom are
composed of epoxy resins and polymers that are radiologically tissue equivalent—
specifically, to soft tissue, inflated lung, brain, and bone (CIRS 2010). The assembled
phantom in the treatment position for the lower spinal field at AUBMC is shown in figure 1.
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Kilovoltage computed tomography (CT) images were acquired for treatment planning using
methods similar to those used for photon CSI at each institution. At MD Anderson, the
phantom was placed in the head-first, supine position, the images were reconstructed with a
slice thickness of 0.25 cm, and the image set covered the full length of the phantom. At
AUBMC, the phantom was placed in the head-first, prone position, the images were
reconstructed with a slice thickness of 1 cm, and the image set covered the full length of the
phantom.
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Using commercial TPSs and the CT image sets, we created two CSI treatment plans. The
TPS at MD Anderson was Eclipse (version 8.9, Varian Medical Systems, Inc., Palo Alto,
California) with the analytical anisotropic algorithm (AAA) dose algorithm (Sievinen et al
2005), heterogeneity correction, and a 2-mm calculation grid, and the TPS at AUBMC was
Panther (version 5.01, Prowess Inc., Concord, California) with the collapsed cone
convolution superposition algorithm (Ahnesjo 1989), heterogeneity correction, and a 3-mm
calculation grid. The treatment plans in both clinics comprised the following primary
treatment fields: two lateral opposed cranial fields and two posterior-anterior spinal fields.
Boost fields were not used. The spinal fields were matched so that the proximal field edges
met just posterior of the spinal cord. Cranial and upper spinal fields were matched by using a
collimator rotation for the cranial fields so that the inferior edge of the cranial fields matched
with the superior edge of the upper spinal field. No couch rotation was applied. The plans
were designed to deliver the prescription to the brain and cord while keeping the dose at any
point in the cord or brain below 115% of the prescribed dose and blocking the face below
the anterior and middle cranial fossae. A prescribed dose, DRx, of 30.6 Gy was used for the
treatment plans and was delivered in a single fraction during the phantom irradiations.
Additional details about the treatment fields are listed in table 1.
2.3. Measuring absorbed dose
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TLD measurements of absorbed dose were made in the anthropomorphic phantom to
determine the out-of-field stray radiation dose relative to the in-field therapeutic radiation
dose. The linear accelerators used in this study were calibrated according to the American
Association of Physicists in Medicine Task Group 51 calibration protocol (Almond et al
1999) by a medical physicist certified by the American Board of Radiology. Additionally,
the outputs of the linear accelerators were verified to within 2% on the days of phantom
irradiation. In the measurement at MD Anderson, there were 72 TLD locations in organs and
tissues throughout the phantom outside of the field or near the field edge. In the
measurement at AUBMC, there were 209 TLD locations: 184 were in organs and tissues
throughout the phantom outside of the field or near the field edge, 20 were attached to the
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surface of the phantom to measure skin dose, 3 were at in-field calculation points to verify
delivery of the prescribed dose, and 2 were kept outside of the treatment room to quantify
background radiation at the facility. A list that maps the TLD locations to organs at risk for
radiation-induced cancer was provided by the phantom manufacturer, which included brain,
eyes, thyroid, bone marrow, esophagus, thymus, breasts, lungs, liver, pancreas, gall bladder,
spleen, stomach, kidneys, adrenals, intestine, prostate, bladder, and testicles.
The dosimeters were composed of lithium fluoride TLD-100 powder capsules (Quantaflux
Radiological Services, San Jose, California). This TLD is suitable for measuring out-of-field
photon dose in 6-MV radiotherapy (Kry et al 2007, Scarboro et al 2010). The TLDs were
calibrated and read by certified technicians at the Radiological Physics Center (MD
Anderson, Houston, Texas), which includes an accredited dosimetry calibration laboratory.
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The absorbed doses at all TLD locations were collected from the TLD measurements and
from the TPS calculations at points corresponding to the TLD locations and compared. The
values of D were reported relative to the prescribed therapeutic dose of 30.6 Gy, or D/DRx
(in cGy/Gy), for the treatment plan.
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The overall uncertainty of the absorbed dose measured by each in-field TLD was 2.5%
(Kirby et al 1992). We assumed the uncertainty in the in-field dose calculation would be
approximately 2% on the basis of validation measurements obtained at the time of
commissioning of each linear accelerator. We did not account for the possibility of
systematic uncertainty in the absorbed dose measured by each outof-field TLD because of
the non-uniformity of photon spectral fluence in that region (see section 4), however, we
would estimate this uncertainty to be less than 12% (Kry et al 2006, Olko et al 2006,
Scarboro et al 2011). No information about the uncertainty in the out-of-field dose
calculations by the TPSs was available from the manufacturers.
2.4. Distance from the field edge
Absorbed dose in each TLD was plotted as a function of distance from the field edge, r.
Distance from the field edge was chosen as the model’s main parameter because, within
about 30 cm of the field edge, patient scatter and head scatter are the primary components of
out-of-field dose (Kase et al 1983, Stovall et al 1995, Ruben et al 2011) and because in CSI,
most points in organs and tissues that are sensitive to radiation damage are within 30 cm of
the field edge.
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Values of r were determined using the following method. The Cartesian coordinates of each
TLD location in the Digital Imaging and Communications in Medicine (DICOM) patient
coordinate system (IEC 2000) (figure 1) were identified to within ±0.5 cm for each TLD
location using the TPS. The field edge was defined by the boundary of the 50% isodose
surface in the TPS, including points lateral to each field and within the geometric path of the
field but beyond 50% isodose surface. The 50% isodose surface was converted
automatically to a contoured structure using the TPS and exported to an RTSTRUCT
DICOM file. Using in-house computational codes on that DICOM file, we extracted the
coordinates of each node of the polygon defining the field edge. Then, for each TLD
location, we found the coordinates of the node having the shortest distance to that TLD
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location. This point was determined to within ±0.5 cm. The distance, r, between the two
points was calculated using the Euclidean norm, and r was applied to each of the TLD
locations. A minor limitation of this process was that the physical distance was used for each
point rather than the water-equivalent distance. However, because a large number of TLD
locations were used to optimize the parameters of the model, with various materials across
the distances, it is reasonable to assume that this did not appreciably influence the
applicability of our model. The error in r was taken as the root sum of squares of each
independent error in position, or ±0.7 cm.
2.5. Analytical model of dose as a function of distance from the field edge
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Following the methods of Zhang et al (2010), we constructed a model having two Gaussian
components, with a term for locations near to the composite field edge and a term for
locations farther from the composite field edge. Previous experimental studies have
suggested exponential (Stovall et al 1995) and power-law (Georgiev 2009) relationships
between absorbed dose and distance from the field edge. In each measurement, parameters
were fit to a double-Gaussian model for absorbed dose, D (in cGy/Gy), versus r (in cm) as
follows:

(1)
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where σ1 and σ2 were the standard deviations of each Gaussian component, μ1 and μ2 were
the means of each Gaussian component, and α1 and α2 were applied to scale the magnitude
of each Gaussian component. The parameters σ1, σ2, μ1, μ2, α1, and α2 were allowed to
vary. The two Gaussian components were analyzed together and their parameters were fit to
the model by minimizing the root mean square deviation, RMSD. The RMSD (in cGy/Gy)
was defined as

(2)
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for each TLD location, i, evaluated for n TLD locations. Because the slope of dose versus
distance from the field edge was sharp near the field, the uncertainty in position resulted in a
large uncertainty in dose. The penumbra from the beam data for the clinical commissioning
of the linear accelerators was approximately 0.8 cm for fields similar to those in this study.
Therefore, we limited the fitting of the model to TLD locations that were at least 0.3 cm
from the field edge (n = 71 for the MD Anderson measurement and n = 169 for the AUBMC
measurement). Because of the known inaccuracies of the TPS in calculating dose in the infield build-up region, to avoid incorrectly influencing the out-of-field results and model, we
excluded those points in the model fitting.
Upper and lower confidence limits were defined to contain 95% of the data points. For the
model applied to each data set, a confidence limit, CL, was defined as a multiplicative-factor
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increase in D plus or minus the RMSD between the model-predicted dose and the measured
or calculated dose, or
(3)

where A was the multiplicative-factor. The empirical multiplicative factors were determined
separately for the confidence limits of each data set so that 95% of the data points were
within the confidence limits.

3. Results
3.1. Measured and calculated absorbed dose
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The field edge calculated by the TPS in the MD Anderson clinic is shown in figure 2, and
the field edge and the location of the calculation points from each field calculated by the
TPS in the AUBMC clinic are shown in figure 3. With the exceptions noted in section 2.5,
points inside the field edge were considered locations of in-field dose, and points outside the
field edge were considered out-of-field dose. In the AUBMC measurement, more TLD
locations were in-field, and the in-field doses are listed in table 2 by organ. Of the 36 in-field
locations, 10 had differences between the measured and calculated D values of more than
6%. These locations were in sharp gradients in the dose distribution, e.g., near the field edge
and build-up regions. At the calculation points for each field, where the dose gradient was
not sharp, the measured D values were within 2% of the calculated D values. This result
supports the use of these dosimeters to measure absorbed dose up to at least 30 Gy in
radiotherapy beams. The broad range of dose values within some organs (skin, liver, bone
marrow of the ribs, and rectum) reflects the fact that these organs contain sharp dose
gradients.
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The out-of-field absorbed dose values versus distance from field edge for both the TLD
measurements and the TPS calculations are plotted in figure 4a in the MD Anderson setting
(Varian Clinac 2100) and figure 4b for the AUBMC setting (Siemens Artiste). In the latter
setting, with increasing distance, the dose decreased more rapidly very near the field edge (r
< 1.0 cm), less rapidly near the field edge (1.0 cm ≤ r < 2.5 cm) and gradually away from
the field edge (r ≥ 2.5 cm). However, in the former setting, the dose decreased less rapidly
very near and near the field edge (r < 2.5 cm) and gradually away from the field edge (r ≥
2.5 cm).
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In both cases, away from the field edge, the TPS generally underestimated the absorbed
dose, and more so at AUBMC with the Siemens Artiste and the Prowess Panther TPS. This
result is illustrated in figures 4c and 4d, which plots the ratio of absorbed dose calculated by
the TPS to the corresponding measured absorbed dose. For all points outside the field edge,
the average ratio of TPS dose to TLD dose was 0.87 (standard deviation 0.24) and 0.59
(standard deviation 0.27) for the MD Anderson and AUBMC clinics, respectively. For r >
1.0 cm, the average ratio of TPS dose to TLD dose was 0.86 (standard deviation 0.24) and
0.56 (standard deviation 0.19) for the MD Anderson and AUBMC clinics, respectively. In
the AUBMC measurement, very near (r < 1.0 cm), near (1.0 cm ≤ r < 2.5 cm), and away (r
≥ 2.5 cm) from the field edge, the average ratios were 0.92, 0.88, and 0.86 (standard
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deviations 0.20, 0.12, and 0.28), respectively. In the AUBMC measurement, these average
ratios were 1.07, 0.60, and 0.55 (standard deviations 0.76, 0.13, and 0.21), respectively.
3.2. Model of dose as a function of distance from the field edge
The double-Gaussian model parameters were fit to the measured data separately for the
measurement in each clinic. Parameter values are listed in table 3. The model-predicted
curves of absorbed dose as a function of distance from the field edge are plotted in figure 5
along with the measured data. In the near-field region (r < 2.5 cm), the data for the MD
Anderson measurement had a steeper slope than data for the AUBMC measurement.
Because of this, the coefficient of the first term (α1) was much larger for the AUBMC clinic
than the MD Anderson clinic. Away from the field (r ≥ 2.5 cm), the out of field dose curves
versus distance were very similar in shape, giving them comparable values of sigma for the
second term of the double-Gaussian model (σ2).
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The confidence limits were slightly narrower for the MD Anderson data than for the
AUBMC data. For the confidence limits in the MD Anderson measured data, the
multiplicative factor was 0.18, and the RMSD of the deviation between the fit and the data
was 0.91 cGy/Gy. Both values were larger for the confidence limits in the AUBMC
measured data, with a multiplicative factor of 0.20, and the RMSD between the fit and the
data was 1.67 cGy/Gy.

4. Discussion
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In two different clinical settings, we measured out-of-field dose for a photon CSI and fit an
analytical model to the data. The model was tested separately with measured data from MD
Anderson, using a Varian Clinac 2100 linear accelerator, and with measured data from
AUBMC, using a Siemens Artiste linear accelerator. Our results show that out-of-field
absorbed dose in CSI decreases with increasing distance from the field edge, approximately
following a double-Gaussian model. This model estimated out-of-field dose particularly well
for distances greater than 1 cm from the field edge whereas the TPS calculations
systematically underestimated the dose in this region. Between the two clinics, the fitted
parameters of the model were different near the field and similar away from the field edge.
Based on these findings, it appears that a hybrid approach is most appropriate in estimating
out-of-field dose in photon CSI, in which the TPS is used in regions of high dose or sharp
dose gradients, i.e., in the in-field and very-near-field (r < 1 cm) regions, and the analytical
model is used elsewhere.
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Our dose measurements and fitted model parameters were specific to the treatment site,
treatment apparatus, and treatment technique used. The model parameters found in this
study may be applied directly for 6-MV photon CSI with linear accelerators and multileaf
collimators similar to the two settings in this study (i.e., delivered with three-dimensional
conformal or very similar radiotherapy) but should be reassessed for clinics with different
linear accelerators or very different treatment techniques (e.g., intensity-modulated radiation
therapy). The findings of other previous studies support this view. For example, Stovall et al
(1995) reported out-of-field doses for 6-MV 10 cm × 10 cm reference fields delivered by
another commercial linear accelerator (Clinac 2100C, Varian Medical Systems, Inc., Palo
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Alto, California) without a multileaf collimator that were about a factor of 2 lower than our
absorbed dose values. In another study, for pelvic fields to treat prostate cancer delivered
with 18-MV intensity-modulated radiation therapy (21EX, Varian Medical Systems, Inc.,
Palo Alto, California), Kry et al (2009) reported out-of-field photon absorbed doses that
were about a factor of 10 less than our values.
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Our findings are in good agreement with previous out-of-field dose studies in the literature.
In the most closely-matched study, Georgiev (2009) measured the absorbed dose in organs
in a pediatric anthropomorphic phantom for a 6-MV CSI delivered with three-dimensional
conformal radiotherapy by a with a Varian 21EX linear accelerator. He reported dose values
at 2.26 cGy/Gy and 1.18 cGy/Gy in the breast bud and pelvic bone marrow, respectively,
while our dose values in the AUBMC measurement setting were 3.80 cGy/Gy and 4.62
cGy/Gy in the breast and pelvic bone marrow regions, respectively. Considering that he used
a different linear accelerator and phantom, his results were in reasonably good agreement
with ours. The variation in out-of-field dose between studies underscores the importance of
re-fitting the measurement-based parameters in the model to be specific to the treatment
apparatus, site, and technique by minimizing the RMSD. The model may also be applicable
to other treatment sites. However, this possibility should first be confirmed by performing
experiments with conditions similar to those in our study.
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At high dose points in a region with a sharp gradient, e.g., near the field edge, the dose
measured by the TLDs generally did not match the dose predicted by the TPS. In this region,
even a small uncertainty in the location of the TLD (estimated at ±0.7 cm), together with the
possibility of a sharp dose gradient, may have caused a large discrepancy between the TPS
prediction and the TLD measurement. Additionally, other factors may have contributed to
this discrepancy, for example, the difference in the beam quality in our clinical scenario
versus reference conditions. For these reasons, we recommend using TPS calculations for
dosimetric analysis of in-field or very-near-field (r < 1 cm) dose and not doses from TLDs
or from the model developed in this study.
Except in the region very near the field edge (r < 1.0 cm), the TPS underestimated the outof-field dose, and this underestimation generally increased with distance from the field edge.
These findings agree with those of Howell et al (2010) for a different treatment site. They
found that, for a 6-MV mantle field irradiation, their TPS underestimated the out-of-field
dose by an average of 40% for 3.75 < r < 11.25 cm and that the underestimation increased
with increasing distance from the field edge. This confirms the importance of using a hybrid
approach such as the one developed in this study instead of relying solely on a TPS to
calculate dose throughout a patient's body.
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This study had three notable strengths. First, the out-of-field dose measurements were
performed in clinically-realistic fields and in a phantom designed to simulate an actual
patient. Previous out-of-field dose studies were based on non-clinical or reference fields.
Second, it provided an analytical model for potential applications in other clinics or
laboratories making similar out-of-field measurements. This model is useful for CSI studies
that require estimates of out-of-field dose, for example studies that assess the incidence of
biological effects in healthy tissue. Third, the model was tested and shown to be applicable
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in two different clinical scenarios, with linear accelerators and multileaf collimators from
different manufacturers.
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One limitation of our approach to determining out-of-field dose is that this model does not
take into account the depth dependence of out-of-field dose. For example, although some
TLD locations were included in the parameter fitting that were in the geometric path of the
field but beyond the distal 50% isodose surface, the model should not be applied in this
region. This limitation of the model may be important in complex field setups, e.g., arc
therapy. However, in the case of photon CSI, this is a minor limitation because the 50%
isodose surface extends to or near the distal surface of the patient along the beam path.
Another minor limitation of our study was the imprecise determination of distance from the
field edge, but this limitation only weakly affects the estimation of dose for r > 1 cm, which
is our recommended minimum distance at which to apply this model. Finally, the variations
in photon spectral fluence for locations out of field can affect the accuracy of TLD
measurements. Scarboro et al (2011) observed a systematic overestimation by TLDs used in
non-calibration conditions, e.g., out-of-field dose measurements, and proposed correction
factors between 0.88 to 0.99. However, it was infeasible to apply these factors in our study
having composite plans, elongated fields, and unknown photon spectral fluence and mean
energy at each TLD location. Therefore, based on their findings, the absorbed dose values in
our TLD measurements may have been slightly overestimated yet were still a vast
improvement in accuracy compared to the TPS-calculated values.

Author Manuscript

In conclusion, we have measured out-of-field dose for two 6-MV CSIs in two clinical
settings, and we developed and tested an analytical model that estimates the out-of-field
dose versus distance from the field edge. This model is useful for studies that require an
estimate of out-of-field dose for patients who receive 6-MV CSI, for example those that
estimate the risk of radiogenic acute and late effects in healthy tissue.
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Figure 1.

Photograph of the anthropomorphic phantom placed in the treatment position at AUBMC
for the lower spinal field with indicators verifying the source-to-skin distance and the
multileaf collimator leaves. TLDs were placed in plug holes throughout the phantom, and
they were also taped to the surface of the phantom to measure skin dose in these locations.
The axes show the directions of each coordinate in the DICOM patient coordinate system.
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Figure 2.

Dose distribution from the MD Anderson TPS for the CSI of an anthropomorphic phantom
in the mid-sagittal plane (a), axial planes (b-d), and a coronal plane (e). The 50% isodose
line (D = 0.5DRx) is shown in red, and the 100% isodose (D = DRx) line is shown in blue.
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Figure 3.

Dose distribution from the AUBMC TPS for the CSI of an anthropomorphic phantom in the
mid-sagittal plane (a), axial planes of the calculation points (b-d), and a coronal plane (e).
The red isofill represents the region within the field edge (D ≥ 0.5DRx), the blue isofill
represents the region receiving the prescribed dose (D ≥ DRx), and the light blue markers
indicate the locations of the calculation points.
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Figure 4.

Out-of-field absorbed dose versus distance from the field edge for the CSI of an
anthropomorphic phantom, calculated by the TPS (red squares) and measured with TLDs
(blue circles) for (a) the clinic at MD Anderson and (b) the clinic at AUBMC. The ratio of
dose calculated by the TPS to dose measured by the TLD (green triangles) (c) at MD
Anderson and (d) at AUBMC. For clarity, error bars were not plotted. Uncertainties in
values are given in the text in section 2.3.
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Figure 5.

Out-of-field absorbed dose (blue circles) versus distance from the field edge for the CSI of
an anthropomorphic phantom measured with TLDs overlaid by the double-Gaussian model
fit (blue line) to the data, with upper and lower confidence limits (blue dashed lines) for (a)
the measurement at MD Anderson and (b) the measurement at AUBMC.
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Characteristics of each field for the 30.6-Gy, 6-MV CSI treatment. For easier readability, the characteristics of
the fields of feathered junctions and field-in-field fields were averaged (Y-jaw settings) or summed (monitor
units) in this table.
AUBMC Fields
Description

Right Cranial

Left Cranial

Upper Spinal

Lower Spinal

Monitor units

1701

1665

3374

3656

90

270

0

0

Collimator angle (°)

5.0

355.0

0

0

Dose to calculation point (Gy)

15.3

15.3

30.6

30.6

X1 jaw (cm)

−11.4

−9.0

−3.6

−4.0

X2 jaw (cm)

9.0

11.4

3.1

5.0

Y1 jaw (cm)

−9.3

−9.3

−12.4

−17.7

Y2 jaw (cm)

15.1

15.1

9.6

15.0

Water equivalent depth of calculation point (cm)

7.64

7.86

3.74

5.66

Effective square (cm)

15.3

15.3

9.0

10.5

Source-to-skin distance (cm)

93.4

92.0

100.0

100.0

Gantry angle (°)

Author Manuscript

MD Anderson Fields
Description

Right Cranial

Left Cranial

Upper Spinal

Lower Spinal

Monitor units

1700

1700

3009

3213

Gantry angle (°)

270

90

0

0

Collimator angle (°)

8.0

352.0

0

0

Dose to calculation point (Gy)

15.4

15.4

X1 jaw (cm)

−12.0

−12

*

*

32.6

32.4

−4.2

−5.3

Author Manuscript

X2 jaw (cm)

12.0

12

4.3

4.8

Y1 jaw (cm)

−13.0

−13.0

−13.5

−14.0

Y2 jaw (cm)

11.0

11.0

14.6

14.6

Water equivalent depth of calculation point (cm)

10.3

10.3

4.2

6.7

Effective square (cm)

15.0

15.0

13.0

14.9

Source-to-skin distance (cm)

92.1

92.1

100

100

*

The spinal fields were normalized to deliver a DRx of 30.6 Gy before the field-in-field fields were added to the plan. The addition of these fields

resulted in a 6% increase in the absorbed dose at the calculation points of the spinal fields for the MD Anderson plan. This did not affect the model
results because the model was reported in absorbed dose per prescribed dose.
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Values of absorbed dose for each in-field TLD location for AUBMC, measured by a TLD, DTLD, and
calculated by the TPS, DTPS. The organ location of each TLD is listed, but these values were not sampled
representatively throughout the organ.
Organ or location

Author Manuscript
Author Manuscript
Author Manuscript

Slice

DTLD (cGy/Gy)

DTPS (cGy/Gy)

Calculation point, cranial field

3

102.6

100.8

Near calculation point, upper spinal field

15

103.1

102.7

Calculation point, lower spinal field

26

98.0

99.8

Bladder

32

61.2

54.7

Bladder

32

56.1

59.2

Bladder

32

66.7

64.3

Bladder

32

58.9

58.5

Bladder

33

53.4

52.4

Bladder

33

60.3

57.1

Bladder

33

76.6

71.7

Bone marrow – ribs

14

23.9

53.8

Bone marrow – ribs

17

103.6

101.7

Intestine

27

54.4

55.7

Intestine

29

57.0

57.8

Intestine

31

50.5

50.9

Intestine

31

65.9

64.2

Liver

20

63.0

86.0

Liver

20

55.8

71.3

Liver

20

65.9

99.5

Liver

21

44.9

51.3

Liver

21

60.6

61.4

Liver

21

66.8

66.3

Liver

22

53.7

54.6

Liver

22

56.4

56.0

Liver

22

73.1

72.7

Approximate position of ovaries

31

72.2

68.3

Pancreas

23

64.9

64.4

Pancreas

24

75.9

75.5

Rectum

33

11.3

82.4

Skin, mid-posterior

4

92.8

64.5

Skin, mid-posterior

16

63.6

32.8

Skin, mid-posterior

27

67.7

2.8

Stomach

21

70.8

71.6

Stomach

22

56.9

58.2

Stomach

24

55.7

56.9

Stomach

26

53.6

55.0
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Fitting parameters for the double-Gaussian model for the TLD measurements in this study for r > 0.3 cm in
the two clinical settings.
Parameter

MD Anderson model fit

AUBMC model fit

α1 (cm-cGy/Gy)

148.3

224.8

μ1 (cm)

−3.89

−2.16

α1 (cm)

3.57

1.57

α2 (cm-cGy/Gy)

196.7

224.3

μ2 (cm)

−6.80

−7.43

σ2 (cm)

8.58

10.28
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